Zusammenfassung:
Zytokine sind zentrale Mediatoren der Interaktion immunkompetenter Zellen, aber auch der Kommunikation des Immunsystems mit anderen physiologischen Systemen einschließlich des ZNS. Untersuchungen der letzten Jahre zeigen, dass das Neuroleptikum Clozapin in vivo die Freisetzung von Zytokinen und löslichen Zytokinrezeptoren stimuliert. Diese Wirkung betrifft insbesondere das Tumor-Nekrose-Faktor(TNF)-System, das Interleukin(IL)-2-System, IL-6 und granulocyte colony-stimulating factor (G-CSF). Die vorliegende Arbeit diskutiert die Bedeutung dieser Zytokine für die Pathogenese und Pathophysiologie Clozapin-induzierter Nebenwirkungen. Mit großer Wahrscheinlichkeit spielt TNF-α eine wichtige pathogenetische Rolle für das Clozapin-induzierte Fieber und die hämatopoetischen Nebenwirkungen einschließlich der Agranulozytose. Darüber hinaus gibt es Hinweise darauf, dass TNF-α und andere Zytokine auch in endokrin-metabolische (Gewichtszunahme, Induktion einer diabetischen Stoffwechsellage), kardiale (Myokarditis), zentralnervöse (Sedierung) und einige andere, sehr seltene Nebenwirkungen involviert sind. Die Mechanismen, die den immunmodulatorischen Wirkungen von Clozapin zugrunde liegen, sind nicht bekannt, weshalb in diesem Bereich dringender Forschungsbedarf besteht. Von entsprechenden Untersuchungen sind wesentliche Erkenntnisse hinsichtlich der Pathogenese der erwähnten Nebenwirkungen und Impulse für die Entwicklung prophylaktischer und therapeutischer Strategien zu erwarten.
On the Clinical Relevance of Clozapine-Triggered Release of Cytokines and Soluble Cytokine-Receptors:
Cytokines are pivotal mediators of the interaction between immunocompetent cells. Moreover, they mediate the interaction between the immune system and other physiological systems, including the CNS. It has been shown recently that the antipsychotic drug clozapine stimulates in vivo the release of cytokines and soluble cytokine receptors. This holds true for the tumor necrosis factor(TNF)-system, the interleukin(IL)-2-system, IL-6, and granulocyte colony-stimulating factor (G-CSF). The present paper discusses the clinical relevance of these findings for the pathophysiology of clozapine-induced side-effects. It is very probable that TNF-α plays an important role in clozapin-induced fever and in the hematopoetic side effects, including agranulocytosis. Moreover, it is likely that TNF-α and other cytokines are involved in metabolic (weight gain, diabetes), cardiac (myocarditis), CNS (sedation) and other rare side effects. The mechanisms underlying clozapine-induced immunomodulation are unknown. Hence, further studies are very important to enhance our understanding of clozapins's side effects and to develop strategies for prevention and treatment.
Literatur
1
Gross H, Langner E.
Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe.
Wiener Medizinische Wochenschrift.
1966;
116
814-816
2
Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H.
Das klinische Wirkungsbild von Clozapin.
Pharmakopsychiatrie und Neuro-Psychopharmakologie.
1971;
4
201-211
3
Baldessarini R J, Frankenburg F R.
Clozapine. A novel antipsychotic agent.
New England Journal of Medicine.
1991;
324
746-754
4
Meltzer H Y, McGurk S R.
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Schizophrenia Bulletin.
1999;
25
233-255
5
Pickar D.
Prospects for pharmacotherapy of schizophrenia.
Lancet.
1995;
345
557-562
6
Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I P.
Agranulocytosis during treatment with clozapine.
European Journal of clinical Pharmacology.
1977;
11
193-198
7
Pisciotta A V.
Agranulocytosis induced by certain phenothiazine derivatives.
Journal of the American Medical Association.
1969;
208
1862-1868
8
Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A.
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
New England Journal of Medicine.
1993;
329
162-167
9
Lambertenghi D G.
Blood dyscrasias in clozapine-treated patients in Italy.
Haematologica.
2000;
85
233-237
10
Gerson S L.
G-CSF and the management of clozapine-induced agranulocytosis.
Journal of Clinical Psychiatry.
1994;
55 Suppl B
139-142
11
Blum A, Mauruschat W.
Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika - unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin.
Pharmakopsychiatrie.
1972;
5
155-169
12 Pollmächer T. Schlaf, Immunsystem und Neuroleptika - ein Beitrag zur experimentellen Psychoneuroimmunologie. München: MMV Verlag 2000
13
Dinarello C A.
The interleukin-1 family: 10 years of discovery.
FASEB Journal.
1994;
8
1314-1325
14
Pollmächer T, Hinze-Selch D, Mullington J.
Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.
Journal of Clinical Psychopharmacology.
1996;
16
403-409
15
Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T.
Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.
Psychopharmacology (Berl).
2000;
149
163-169
16
Monteleone P, Fabrazzo M, Tortorella A, Maj M.
Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.
Psychiatry Research.
1997;
71
11-17
17
Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J.
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.
American Journal of Psychiatry.
1997;
154
1763-1765
18
Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D.
The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.
Pharmacopsychiatry.
1997;
30
118-121
19
Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F.
Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors.
Archives of General Psychiatry.
1995;
52
877-878
20
Maes M, Meltzer H Y, Bosmans E.
Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.
Acta Psychiatrica Scandinavica.
1994;
89
346-351
21
Maes M, Bosmans E, Kenis G, De Jong R, Smith R S, Meltzer H Y.
In vivo immunomodulatory effects of clozapine in schizophrenia.
Schizophrenia Research.
1997;
26
221-225
22
Sperner-Unterweger B, Gaggl S, Fleischhacker W W, Barnas C, Herold M, Geissler D.
Effects of clozapine on hematopoiesis and the cytokine system.
Biological Psychiatry.
1993;
34
536-543
23
Hinze-Selch D, Becker E W, Stein G M, Berg P A, Mullington J, Holsboer F, Pollmächer T.
Effects of clozapine on in vitro immune parameters - a longitudinal study in clozapine-treated schizophrenic patients.
Neuropsychopharmacology.
1998;
19
114-122
24
Jones-Brando L V, Buthod J L, Holland L E, Yolken R H, Torrey E F.
Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1.
Schizophrenia Research.
1997;
25
63-70
25
Blalock J E.
A molecular basis for bidirectional communication between the immune and neuroendocrine systems.
Physiological Reviews.
1989;
69
1-32
26
Hampson M E.
Clozapine-induced thrombocytosis.
British Journal of Psychiatry.
2000;
176
400
27
Assion H J, Kolbinger H M, Rao M L, Laux G.
Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine.
Pharmacopsychiatry.
1996;
29
227-228
28
Rudolf J, Grond M, Neveling M, Heiss W D.
Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.
J Neural Transm.
1997;
104
1305-1311
29
Alvir J M, Lieberman J A, Safferman A Z.
Do white-cell count spikes predict agranulocytosis in clozapine recipients?.
Psychopharmacol Bull.
1995;
31
311-314
30
Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker W W.
Clozapine-induced transient white blood count disorders.
Journal of Clinical Psychiatry.
1994;
55
429-432
31
Hummer M, Sperner-Unterweger B, Kemmler G, Falk M, Kurz M, Oberbauer H, Fleischhacker W W.
Does eosinophilia predict clozapine induced neutropenia?.
Psychopharmacology (Berl).
1996;
124
201-204
32
van der Poll T, van Deventer S J, Hack C E, Wolbink G J, Aarden L A, Buller H R, ten Cate J W.
Effects on leukocytes after injection of tumor necrosis factor into healthy humans.
Blood.
1992;
79
693-698
33
Steward W P.
Granulocyte and granulocyte-macrophage colony-stimulating factors.
Lancet.
1993;
342
153-157
34
Pollmächer T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H, Galanos C, Holsboer F.
Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men.
Blood.
1996;
87
900-905
35
Williams D P, Pirmohamed M, Naisbitt D J, Uetrecht J P, Park B K.
Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.
Molecular Pharmacology.
2000;
58
207-216
36
Turbay D, Lieberman J, Alper C A, Delgado J C, Corzo D, Yunis J J, Yunis E J.
Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups.
Blood.
1997;
89
4167-4174
37
Schuld A, Kraus T, Hinze-Selch D, Haack M, Pollmächer T.
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.
Acta Psychiatrica Scandinavica.
2000;
102
153-155
38
Jensen V E, Gotzsche O.
Allergic myocarditis in clozapine treatment.
Ugeskr Laeger.
1994;
156
4151-4152
39
Lilleng P, Morild I, Hope M.
Clozapine and myocarditis.
Tidsskr Nor Laegeforen.
1995;
115
3026-3027
40
Bandelow B, Degner D, Kreusch U, Rüther E.
Myocarditis under therapy with clozapine.
Schizophrenia Research.
1995;
17
293-294
41
Khalil N.
Peri-/Myokarditis unter Clozapin (Leponex).
Psychiatr Prax.
1997;
24
46
42
Killian J G, Kerr K, Lawrence C, Celermajer D S.
Myocarditis and cardiomyopathy associated with clozapine.
Lancet.
1999;
354
1841-1845
43
Meldrum D R.
Tumor necrosis factor in the heart.
American Journal of Physiology.
1998;
274
R577-R595
44
Feldman A M, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y Y, McTiernan C.
The role of tumor necrosis factor in the pathophysiology of heart failure.
J Am Coll Cardiol.
2000;
35
537-544
45
Kellner M, Wiedemann K, Krieg J C, Berg P A.
Toxic hepatitis by clozapine treatment.
American Journal of Psychiatry.
1993;
150
985-986
46
Bauer M.
Concurrent agranulocytosis and acute hepatitis resulting from combination of classic neuroleptics and subsequent successful clozapine treatment.
Pharmacopsychiatry.
1995;
28
29-31
47
Worrall R, Wilson A, Cullen M.
Dystonia and drug-induced hepatitis in a patient treated with clozapine.
American Journal of Psychiatry.
1995;
152
647-648
48
Thatcher G W, Cates M, Bair B.
Clozapine-induced toxic hepatitis.
American Journal of Psychiatry.
1995;
152
296-297
49
Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J.
Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity.
Gastroenterology.
1997;
112
1707-1709
50
Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker W W.
Hepatotoxicity of clozapine.
Journal of Clinical Psychopharmacology.
1997;
17
314-317
51
Frankenburg F R, Kando J.
Eosinophilia, clozapine, and pancreatitis [letter].
Lancet.
1992;
340
251
52
Bergemann N, Ehrig C, Diebold K, Mundt C, von Einsiedel R.
Asymptomatic pancreatitis associated with clozapine.
Pharmacopsychiatry.
1999;
32
78-80
53
Cerulli T R.
Clozapine-associated pancreatitis.
Harvard Review of Psychiatry.
1999;
7
61-63
54
Norman J.
The role of cytokines in the pathogenesis of acute pancreatitis.
Am J Surg.
1998;
175
76-83
55
Robinson D, Fenn H, Yesavage J.
Possible association of parotitis with clozapine.
American Journal of Psychiatry.
1995;
152
297-298
56
Hinze-Selch D, Becker E W, Stein G, Schreiber W, Pollmächer T.
Clozapine-induced parotitis - an immunological cause?.
American Journal of Psychiatry.
1996;
153
840
57
Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J.
Antipsychotic-induced weight gain: a comprehensive research synthesis.
American Journal of Psychiatry.
1999;
156
1686-1696
58
Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J C, Hebebrand J.
Serum leptin levels increase rapidly after initiation of clozapine therapy.
Molecular Psychiatry.
1998;
3
76-80
59
Auwerx J, Staels B.
Leptin.
Lancet.
1998;
351
737-742
60
Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, Pollmächer T.
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
American Journal of Psychiatry.
1999;
156
312-314
61 Hinze-Selch D, Schuld A, Kraus T, Kühn M, Uhr M, Haack M, Pollmächer T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology, in press
62
Gainsford T, Alexander W S.
A role for leptin in hemopoieses?.
Mol Biotechnol.
1999;
11
149-158
63
Ahima R S, Bjorbaek C, Osei S, Flier J S.
Regulation of neuronal and glial proteins by leptin: implications for brain development.
Endocrinology.
1999;
140
2755-2762
64
Finck B N, Johnson R W.
Tumor necrosis factor-alpha regulates secretion of the adipocyte-derived cytokine, leptin.
Microsc Res Tech.
2000;
50
209-215
65
Langhans W, Hrupka B.
Interleukins and tumor necrosis factor as inhibitors of food intake.
Neuropeptides.
1999;
33
415-424
66
Argilés J M, López-Soriano J, Busquets S, López-Soriano F J.
Journey from cachexia to obesity by TNF.
FASEB Journal.
1997;
11
743-751
67
Bulló-Bonet M, García-Lorda P, López-Soriano F J, Argilés J M, Salas-Salvadó J.
Tumour necrosis factor, a key role in obesity?.
FEBS Letters.
1999;
451
215-219
68
Hauner H, Bender M, Haastert B, Hube F.
Plasma concentrations of soluble TNF-alpha receptors in obese subjects.
Int J Obes Relat Metab Disord.
1998;
22
1239-1243
69
Moller D E.
Potential Role of TNF-alpha in the Pathogenesis of Insulin Resistance and Type 2 Diabetes.
Trends in Endocrinology & Metabolism.
2000;
11
212-217
70
Melkersson K I, Hulting A L, Brismar K E.
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.
Journal of Clinical Psychiatry.
1999;
60
783-791
71
Hägg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R.
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.
Journal of Clinical Psychiatry.
1998;
59
294-299
72
Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C.
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
American Journal of Psychiatry.
2000;
157
975-981
73
Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois M L, Vergnot V, Gin H.
Diabetes as a result of atypical anti-psychotic drugs - a report of three cases.
Diabet Med.
2000;
17
484-486
74
Maule S, Giannella R, Lanzio M, Villari V.
Diabetic ketoacidosis with clozapine treatment.
Diabetes Nutr Metab.
1999;
12
187-188
75
Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N.
Diabetic ketoacidosis associated with clozapine treatment.
Diabetes Care.
1999;
22
176-177
76
Smith H, Kenney-Herbert J, Knowles L.
Clozapine-induced diabetic ketoacidosis.
Australian & New Zealand Journal of Psychiatry.
1999;
33
120-121
77
Ai D, Roper T A, Riley J A.
Diabetic ketoacidosis and clozapine.
Postgrad Med J.
1998;
74
493-494
78
Pierides M.
Clozapine monotherapy and ketoacidosis.
British Journal of Psychiatry.
1997;
171
90-91
79
Peterson G A, Byrd S L.
Diabetic ketoacidosis from clozapine and lithium cotreatment.
American Journal of Psychiatry.
1996;
153
737-738
80
Koval M S, Rames L J, Christie S.
Diabetic ketoacidosis associated with clozapine treatment.
American Journal of Psychiatry.
1994;
151
1520-1521
81
Popli A P, Konicki P E, Jurjus G J, Fuller M A, Jaskiw G E.
Clozapine and associated diabetes mellitus.
Journal of Clinical Psychiatry.
1997;
58
108-111
82
Kluger M J.
Fever: role of pyrogens and cryogens.
Physiological Reviews.
1991;
71
93-127
83
Shoham S, Davenne D, Cady A B, Dinarello C A, Krueger J M.
Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep.
American Journal of Physiology.
1987;
253
R142-R149
84
Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D, Mullington J.
Schlaf und Schläfrigkeit im Rahmen von Infektionen und im Rahmen experimenteller Immunmodulation beim Menschen.
Somnologie.
2000;
4
68-78
85 Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D, Mullington J. Experimental immunomodulation, sleep and sleepiness in humans. Annals of the New York Academy of Sciences, in press
86
Mullington J, Korth C, Hermann D M, Orth A, Galanos C, Holsboer F, Pollmächer T.
Dose-dependent effects of endotoxin on human sleep.
American Journal of Physiology Regulatory, Integrative and Comparative Physiology.
2000;
278
R947-R955
87
Wetter T C, Lauer C J, Gillich G, Pollmächer T.
The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs.
Journal of Psychiatric Research.
1996;
30
411-419
88
Hinze-Selch D, Mullington J, Orth A, Lauer C J, Pollmächer T.
Effects of clozapine on sleep: a longitudinal study.
Biological Psychiatry.
1997;
42
260-266
89
Hinze-Selch D, Mullington J, Pollmächer T.
Sleep during clozapine-induced fever in a schizophrenic patient.
Biological Psychiatry.
1995;
38
690-693
90
Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D.
Effects of antipsychotic drugs on cytokine networks.
Journal of Psychiatric Research.
2000;
34
369-382
91
Hopkins S J, Rothwell N J.
Cytokines and the nervous system I: expression and recognition.
Trends in Neurosciences.
1995;
18
83-88
92
Tracey K J, Cerami A.
Tumor necrosis factor: an updated review of its biology.
Crit Care Med.
1993;
21
S415-S422
Priv.-Doz. Dr. med. Thomas Pollmächer
Max Planck Institut für Psychiatrie
Kraepelinstrasse 10
80804 München
eMail: E-mail: topo@mpipsykl.mpg.de